RT @JACCJournals: In patients getting anthracycline chemotherapy, carevedilol doesn’t impact LVEF reduction but does reduce troponin levels…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @md_arianemacedo: CECCY trial ! https://t.co/CHKJH9YZTL
RT @JACCJournals: In patients getting anthracycline chemotherapy, carevedilol doesn’t impact LVEF reduction but does reduce troponin levels…
RT @JACCJournals: In patients getting anthracycline chemotherapy, carevedilol doesn’t impact LVEF reduction but does reduce troponin levels…
RT @JACCJournals: In patients getting anthracycline chemotherapy, carevedilol doesn’t impact LVEF reduction but does reduce troponin levels…
RT @JACCJournals: In patients getting anthracycline chemotherapy, carevedilol doesn’t impact LVEF reduction but does reduce troponin levels…
RT @JACCJournals: In patients getting anthracycline chemotherapy, carevedilol doesn’t impact LVEF reduction but does reduce troponin levels…
RT @JACCJournals: In patients getting anthracycline chemotherapy, carevedilol doesn’t impact LVEF reduction but does reduce troponin levels…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
In patients getting anthracycline chemotherapy, carevedilol doesn’t impact LVEF reduction but does reduce troponin levels & diastolic dysfunction: https://t.co/M58VyNkd8G. #JACC https://t.co/AADoHwgSbS
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @md_arianemacedo: CECCY trial ! https://t.co/CHKJH9YZTL
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
Carvedilol reduces extnt of #troponin elevation & development diastolic dysfunction during anthracyclin chemotherapy for breast cancer; incidence of LVSD (in both arms of trial) high @JACCJournals @BSHeartFailure @pumpinghearts @CardioOnline @cardioonc
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
Carvedilol for Prevention of Chemotherapy-Related #Cardiotoxicity The CECCY Trial https://t.co/zN640hx15U https://t.co/zN640hx15U
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @md_arianemacedo: CECCY trial ! https://t.co/CHKJH9YZTL
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @md_arianemacedo: CECCY trial ! https://t.co/CHKJH9YZTL
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @md_arianemacedo: CECCY trial ! https://t.co/CHKJH9YZTL
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
CECCY trial ! https://t.co/CHKJH9YZTL
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
RT @JACCJournals: New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chem…
New #JACC study shows beta-blockers have no impact on incidence of #LVEF reduction in patients getting anthracycline chemotherapy: https://t.co/WKFZPsDle3. https://t.co/X0DtaMVHVq
RT @JACCJournals: Prospective trial evaluates carvedilol for prevention of chemotherapy cardiotoxicity: https://t.co/woNhdhuSNl. #JACC http…
RT @JACCJournals: Prospective trial evaluates carvedilol for prevention of chemotherapy cardiotoxicity: https://t.co/woNhdhuSNl. #JACC http…
RT @JACCJournals: Prospective trial evaluates carvedilol for prevention of chemotherapy cardiotoxicity: https://t.co/woNhdhuSNl. #JACC http…
RT @Ron_Witteles: Ummmm... let’s just say that I have a wee bit of a problem with the statistics on this figure. Data also different than…
Ummmm... let’s just say that I have a wee bit of a problem with the statistics on this figure. Data also different than as listed in Table 2. And Table 2 average three-week troponin values listed below the supposed minimum based on Methods. 🤔 #CardioOnc h
Parabens! excelente trial! um exemplo de tenacidade e fé no trabalho bem feito https://t.co/CuTP5clKYu
RT @JACCJournals: Prospective trial evaluates carvedilol for prevention of chemotherapy cardiotoxicity: https://t.co/woNhdhuSNl. #JACC http…
RT @JACCJournals: Prospective trial evaluates carvedilol for prevention of chemotherapy cardiotoxicity: https://t.co/woNhdhuSNl. #JACC http…
RT @JACCJournals: Prospective trial evaluates carvedilol for prevention of chemotherapy cardiotoxicity: https://t.co/woNhdhuSNl. #JACC http…
RT @JACCJournals: Prospective trial evaluates carvedilol for prevention of chemotherapy cardiotoxicity: https://t.co/woNhdhuSNl. #JACC http…
RT @JACCJournals: Prospective trial evaluates carvedilol for prevention of chemotherapy cardiotoxicity: https://t.co/woNhdhuSNl. #JACC http…
Wonder if they monitored for too short a period of time. #CardioOnc https://t.co/Mi1HJstGs4
RT @JACCJournals: Prospective trial evaluates carvedilol for prevention of chemotherapy cardiotoxicity: https://t.co/woNhdhuSNl. #JACC http…
RT @JACCJournals: Prospective trial evaluates carvedilol for prevention of chemotherapy cardiotoxicity: https://t.co/woNhdhuSNl. #JACC http…
RT @JACCJournals: Prospective trial evaluates carvedilol for prevention of chemotherapy cardiotoxicity: https://t.co/woNhdhuSNl. #JACC http…
RT @JACCJournals: Prospective trial evaluates carvedilol for prevention of chemotherapy cardiotoxicity: https://t.co/woNhdhuSNl. #JACC http…